Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Droperidol QT risk management

Executive Summary

Risk management and assessment for QTc prolongation associated with the anesthetic/antiemetic droperidol (Akorn's Inapsine and generics) will be discussed by FDA's Anesthetic & Life Support Drugs Advisory Committee on Nov. 18. Several risk management steps were implemented when the safety concern was discovered in December 2001 (1"The Pink Sheet" Dec. 10, 2001, p. 23). The meeting will be held at the Holiday Inn in Gaithersburg, Md. beginning at 8 a.m. [To 2watch a webcast or video of this and other meetings, go to]....

You may also be interested in...

Droperidol Gets Second-Line, Narrowed Indication Due To Arrhythmia Risk

Updated labeling for Akorn's Inapsine and droperidol generics restricts the drug to second-line use for a narrowed indication due to the risk of fatal cardiac arrhythmias

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts